Intelligence · Clinical Development
Pipeline search results
Programs matching “natural” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 8 pipeline programs matching "natural" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
20240178
Amgen
Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.
1 trial -
Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Promyelocytic Leukaemia
1 trial -
Realgar-Indigo naturalis formula
The First People's Hospital of Lianyungang
Acute Promyelocytic Leukemia
1 trial -
Allogenic expanded Natural Killer Cells (AlloNK1)
Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma (NPC)
1 trial -
Indigo naturalis ointment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Psoriasis
1 trial -
Autologous Natural Killer Cell Therapy
Hospital Authority, Hong Kong
Hepatocellular Carcinoma
1 trial -
Realgar-Indigo Naturalis Formulation Combined with Anlotinib
The First People's Hospital of Lianyungang
Platinum-resistant Ovarian Cancer (PROC)
1 trial -
circulate free methylated EBV DNA
The First People's Hospital of Lianyungang
Extranodal Natural Killer/T-cell Lymphoma
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.